Recent Updates
Recently added Catalysts
CSBR Positive Sentiment

Champions Oncology Announces Appointment of New CEO

Key Takeaway: Champions Oncology has appointed Rob Brainin as CEO, effective August 25, 2025. He succeeds Dr. Ronnie Morris, who will become Executive Chair. Brainin, with over 25 years in life sciences, aims to expand the company's data platform and enhance its therapeutic pipeline. Morris expressed confidence in Brainin's leadership for future growth.
Price reaction · baseline $8.36 (2025-07-17 close) · hit pre-market · 1 other CSBR headline(s) in the window, move may be shared
day 0 close · peak
-4.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Rob Brainin appointed as new CEO effective August 25, 2025.
  • Dr. Ronnie Morris transitions to Executive Chair, remaining involved.
  • Brainin has over 25 years of experience in life sciences.
  • Champions Oncology aims to expand its data offerings.

Full Press Release Details

HACKENSACK, NJ / ACCESS Newswire / July 18, 2025 / Champions Oncology (NASDAQ:CSBR), a leading provider of oncology-focused CRO services specializing in preclinical and clinical specialty testing, today announced that its Board of Directors has appointed Rob Brainin as Chief Executive Officer and member of the Board of Directors, effective August 25, 2025.
Rob, who has served on Champions' Board since 2021, will succeed Dr. Ronnie Morris, who has led the company as CEO since 2017. Dr. Morris will transition to the role of Executive Chair on August 25, supporting the leadership transition while remaining actively involved in the company's strategic initiatives.
"I want to thank Ronnie for his outstanding leadership and vision since 2017, and I am thrilled he will continue to play an integral role as Executive Chair," said Joel Ackerman, Chairman of the Board, who will transition to a Director role. "As we expand beyond our core CRO services into a robust data offering, Rob's expertise and track record of driving growth in innovative life sciences businesses make him the ideal leader to guide Champions through its next chapter."
Rob Brainin brings more than 25 years of experience in life sciences and technology, with a proven ability to scale and grow businesses built on cutting-edge science and data capabilities. He most recently served as Chief Business Officer at Veracyte, an oncology diagnostics company, and previously as CEO of Genuity Science, a company focused on genomics, data, and therapeutic discovery.
"I am honored and excited to join Champions at such a pivotal time," said Brainin. "The strength of Champions' core CRO services provides a tremendous foundation to expand our emerging data platform and advance the pipeline of our discovery therapeutics subsidiary, Corellia AI. I look forward to working alongside this talented team to build on the company's momentum and create value for our customers, employees, and shareholders."
Dr. Morris added, "I am incredibly proud of what we have accomplished together and the outstanding team we have assembled. I have complete confidence that Rob is the right leader to take Champions into its next phase of growth, and I look forward to supporting him and the team in realizing the company's full potential."

Frequently Asked Questions

Who has been appointed as the new CEO of Champions Oncology?

Rob Brainin has been appointed as the new CEO.

When will Rob Brainin officially take over as CEO?

He will officially take over on August 25, 2025.

What role will Dr. Ronnie Morris take after stepping down?

Dr. Ronnie Morris will become the Executive Chair.

What is Rob Brainin's experience in the industry?

He has over 25 years of experience in life sciences and technology.

Last updated: Jul 18, 2025